NVIDIA and Novo Nordisk Join Forces to Accelerate AI-Driven Drug Discovery

• Novo Nordisk to use NVIDIA's AI stack and Gefion supercomputer for drug discovery
• Focus areas include molecule design, single-cell models, and biomedical LLMs
• Gefion also powers AI innovations in healthcare monitoring and rare disease research

NVIDIA has announced a strategic alliance with Novo Nordisk to accelerate drug discovery using the power of AI and supercomputing. The partnership with DCAI's Gefion AI supercomputer, which is based in Denmark, will enable both companies to develop AI models specific to early-stage research and clinical development.

Novo Nordisk plans to leverage NVIDIA's BioNeMo for generative drug design, NeMo and NIM microservices for agentic workflows, and the Omniverse platform for physically accurate simulations.

“AI is essential for every industry, and there’s no other field that will benefit more from acceleration than drug discovery,” said Rory Kelleher, senior director of business development for life sciences at NVIDIA.

Also Read: Unlocking India's Innovation Potential in Pharma

The various initiatives of the partnership are focused on developing models that predict cellular responses to drug candidates, the design of new molecules with drug-like activity, and building biomedical language models by mining scientific literature.

“By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk.